Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal group C conjugate vaccine + acellular pertussis-containing vaccine
- Development stage
- Unknown
- Lead developer
- Public Health England
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The concomitant administration of meningococcal group C (MenC) conjugate vaccines and acellular pertussis-containing booster vaccines refers to a vaccination regimen evaluated in the Phase III/IV 'Multiboost' (or 'Mutliboost') clinical trial conducted by Public Health England. This study assessed the safety and immunogenicity of co-administering these vaccines in adolescents aged 13 to 17 years to inform the United Kingdom's national immunization schedule. The MenC component involved various conjugate vaccines, including Meningitec, Menjugate, NeisVac-C, or the MenC-Hib combination Menitorix. The pertussis component was typically delivered via quadrivalent boosters such as Repevax or IPV-Boostrix, which also provide protection against diphtheria, tetanus, and poliomyelitis. The regimen aims to simplify the adolescent immunization schedule by allowing multiple priority boosters to be administered during a single visit.
- Other names
- Multiboost study intervention
02
Targets
TT (Tetanus toxoid)FHA (Filamentous hemagglutinin)FIM2/FIM3 (Fimbriae types 2 and 3)Poliovirus capsid proteinsNeisseria meningitidis group C capsular polysaccharidePRN (Pertactin)FIM2/3 (Bordetella pertussis fimbriae type 2/3)PT (Pertussis toxin)
Beyond the preview
Go deeper on meningococcal group C conjugate vaccine + acellular pertussis-containing vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal group C conjugate vaccine + acellular pertussis-containing vaccine.